Mark Enright

Professor Mark Enright is a Professor of Medical Microbiology at Manchester Metropolitan University's Department of Life Sciences, specializing in genomic epidemiology of antibiotic-resistant pathogens and bacteriophage therapy development. His work bridges clinical microbiology with advanced genomic techniques to combat multidrug-resistant infections.

His educational background includes:

• PhD in Medical Microbiology, University of Aberdeen (1995)
• MSc in Biochemistry, University of Dundee (1990)
• BSc (Hons) in Biological Sciences, University of Stirling (1989)

Enright's research focuses on antibiotic resistance mechanisms in Gram-positive and Gram-negative pathogens, with groundbreaking work on bacteriophage-based therapeutics targeting Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae. His laboratory employs whole-genome sequencing and core-genome MLST to track pathogen evolution, biofilm formation, and horizontal gene transfer. Recent projects include developing phage cocktails against cystic fibrosis-related infections and characterizing depolymerases for capsular polysaccharide degradation.

Analysis of his 2015-2025 publications reveals consistent focus on genomic epidemiology of healthcare-associated pathogens, with increasing emphasis on phage therapy applications. His work demonstrates methodological evolution from traditional typing to advanced genomic analyses, particularly in tracking international MRSA transmission and developing phage-based biofilm disruption strategies for wound infections.

His major recognitions include:

• Royal Society University Research Fellowship (2000-2008)
• European Society for Clinical Microbiology Young Investigator Award (2002)

As Editor of the International Journal of Antimicrobial Agents and Section Editor for FEMS Microbiology Letters, Enright shapes antimicrobial research discourse. He serves on editorial boards of Antibiotics and PeerJ, and reviews for Science and Nature. His grant review expertise for Wellcome Trust, MRC, and EU programs informs global research funding priorities. Formerly a Visiting Professor at University of Bath (2011-2014), he maintains strong industry-academia collaborations in antimicrobial development.

His Molecular Microbiology teaching integrates cutting-edge research into curriculum, while his John Dalton Building laboratory develops novel approaches to combat antimicrobial resistance through phage genomics and biofilm disruption technologies.